Drugs / RH5.1
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05385471 | Jan 2023 → Mar 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06958198 | Sep 2025 → Oct 2026 expected | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 1 | NCT06141057 | Jun 2023 → Jul 2025 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04318002 | Jan 2021 → Aug 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05790889 | Apr 2023 → May 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07183371 | Dec 2025 → Dec 2026 expected | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05978037 Comparator | Aug 2023 → Apr 2026 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT02927145 Comparator | Oct 2016 → Jun 2019 | malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RH5.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05385471 ↗ |
| Modality | Vaccine | “The RH5.1 recombinant protein vaccine, targeting the P. falciparum reticulocyte-binding protein homolog 5 (RH5), formulated in AS01B adjuvant.” PMID 34223402 ↗ Jun 2021 |
| Route | Intramuscular | “administered intramuscularly in healthy adults, young children and infants in Tanzania” NCT04318002 ↗ |